Name: Pearce IP
Address: Level 5/20 Bond St, Sydney, NSW, 2000, AU
Telephone: (02) 9023 9988
Price range: $$

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Patent litigation in Australia just got a little cheaper

By Naomi Pearce | Apr 08, 2022

Read more

The Full Court’s refusal of leave to appeal today in Novartis AG v Pharmacor Pty Limited [2022] FCAFC 58 is good news for the cost of patent litigation in Australia: it may have jus...
The recipe for success: CSIRO launches bold new protein roadmap

By Pearce IP | Apr 07, 2022

Read more

In the quest for a more sustainable future, not least of all in response to the pressing issues of climate change and global population growth, innovative agri-technology and foodte...
Alvotech settles with AbbVie in Europe, allowing Stada to commercialise adalimumab biosimilar there

By Bioblast Editor | Apr 06, 2022

Read more

Alvotech announced that it has resolved its patent disputes with AbbVie in Europe and selected markets elsewhere relating to Alvotech’s citrate free, high concentration adalimumab (AVT02, biosimilar to Humira®). This follows the resolution of the US litigation between AbbV...
Australian Government commits to claim damages from originator pharmaceutical companies where generic entry is unduly delayed

By Naomi Pearce | Apr 05, 2022

Read more

In its 2022-23 Budget, the Coalition Government has stated that it will continue to fund litigation against originator pharmaceutical companies that prevent generic versions of thei...
Axantia to commercialise ranibizumab biosimilar in the Middle East

By Bioblast Editor | Apr 04, 2022

Read more

Intas announced that it has signed an exclusive license and supply agreement with Axantia, a Middle Eastern pharmaceutical company, for the commercialisation of ranibizumab (biosimilar Lucentis®) in territories including Saudi Arabia, Jordan, Iraq and Lebanon.
Pearce IP BioBlast w/e 1 April 2022

By Naomi Pearce | Apr 04, 2022

Read more

28 Mar 22 | Aurobindo announced that it will acquire certain business assets from Veritaz (the supplier of branded generic formulations and other health care products) for Rs 171 cr...
FDA accepts Dupixent® for priority review

By Bioblast Editor | Apr 04, 2022

Read more

Regeneron announced that the FDA has accepted for Priority Review the sBLA for Dupixent® (dupilumab) for the treatment of eosinophilic esophagitis (EoE).
Fresenius acquires a majority stake in mAbxience and also Ivenix

By Bioblast Editor | Mar 31, 2022

Read more

31 March 22 | Fresenius Kabi announced that it has bought a majority stake (55%) in mAbxience, a company specialising in biosimilars, for an upfront EUR 495 million plus milestone payments, and Ivenix, which has a leading infusion therapy platform, for an upfront US$ 240 mi...
Gene Therapy 22/23 Budget Announcement Big News for Australian Patients, and for Novartis

By Pearce IP | Mar 30, 2022

Read more

The Australian treasurer, Josh Frydenberg used his budget speech yesterday to make several announcements in relation to new pharmaceuticals to be listed in the Australian Pharmaceut...
AU Budget 22-23: Highlights for Health, Pharma/Biopharma, Life Sciences & Agribusiness

By Naomi Pearce | Mar 30, 2022

Read more

In the Coalition Government’s Budget for the financial year 2022-23, it sets out the investments that it would make should the Coalition remain in power after the next election, now...